Biosense Webster News & Events

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

VARIPULSE

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Johnson & Johnson MedTech Presents Pivotal 12-Month Effectiveness and Safety Data from SmartfIRE Study at 2025 EHRA Congress 

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

10 January 2025

VARIPULSE™

The Evolving Landscape of Atrial Fibrillation Ablation: VARIPULSE™ Launches in European Hospitals

22 October 2024

Johnson & Johnson MedTech receives CE Mark for OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

Biosense Webster Completes Enrollment of Omny-IRE Clinical Trial Investigating the OMNYPULSE™ Large-tip Focal Pulsed Field Ablation Catheter

How Our Innovation Restored an Employee’s Heartbeat

How Our Innovation Restored an Employee’s Heartbeat

Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress